Study on the effects of co-administration of lipase inhibitor and Alpha-glucosidase inhibitor in control of weight in obese patient

Determining the Effect of Co-Prescribing Orlistat and Acrobats on Weight Control in Obese People

A randomized clinical trial, blind, double blind, controlled clinical trials, and a sample of 90 subjects who had entered the study by simple sampling after obtaining consent, using a balanced block randomization with three blocks in three groups (30 subjects ) Are placed. All three groups of multivitamin tablets (weekly one) to prevent fat-soluble vitamin deficiencies and 40 mg of dimethicone three times a day will improve the symptoms of bleeding from orlistat and daily acarbose for 6 months.

1- Calculation of BMI and measurement of FBS, TG, LDL, HDL, cholesterol and insulin before and after intervention. 2- Setting up a diet and training the diet appropriately by a nutrition expert 3- Distribution of drugs and body weight measurement, delivery of supplements and monitoring their use, registration of possible side effects of medication, diet and diet monitoring, and physical activity on the checklist on a monthly basis. The design is done at the Endocrine Research Center of Kerman University of Medical Sciences.

Inclusion criteria: aged 20 to 50 years / non-underlying disease and BMI> 30. Exclusion criteria: Cases of cardiovascular / gastrointestinal / malabsorption / hyperlipidemia or hypothyroidism / Cushing's disease / Previously diagnosed diabetes by a doctor or existing documentation

1- Orlistat drug group (3 daily food supplements, 180 mg) 2- Orlistat-Acarbose group (60 mg orlistat 3 times a day with food, 25 mg acarbose three times daily at the start of meal) 3- Control group (multivitamin, weekly 1)

Age, sex, height, weight, BMI, FBS, LDL, HDL, TG, insulin, waist circumference, hip circumference, WHR

After obtaining consent, the patients are divided into three groups based on entering the study and the method of balanced block randomization with triple blocks. The first group received orlistat (three daily food supplements, 180 mg), the second group was orlistat-acarbose (orlistat 60 mg three times daily with food, 25 mg acarbose three times daily at the start of meal) and the group Control (multivitamin, weekly 1).

The blinding of groups is divided by the expert of the research center which is not involved in the implementation of the plan, and is kept in the dark envelope in the package until the end of the design and final analysis at the research center. According to the traditional use group, there is no possibility of blindness for the physician and the patient. But randomization is done in the form of a balanced block randomization in binary groups and four blocks, and the statistician is blind compared to the groups.